Upri: A First Line Antibody Drug Conjugate

The Gloriosa trial is a platinum sensitive meeting so patients who longs they don't progress on platinum they have the option of going to BEV. We're screening those patients early we want to bring MIRV as an option earlier lines of therapy and this is an option right now in clinical trial hopefully in the future it will be available to our patients outside of clinical trial. In terms of where things are heading bladder has two antibody drug conjugates but there's another one in ovary it looks like it's very promising I call it Upri.